Author(s):
Dinesh S. Shinde, Amol R. Pawar, Pankaj S. Patil, Vikas V. Patil
Email(s):
dineshshinde1913@gmail.com
DOI:
10.52711/0974-4150.2026.00081 
Address:
Dinesh S. Shinde*, Amol R. Pawar1,2, Pankaj S. Patil1, Vikas V. Patil1
1Department of Quality Assurance, Kisan Vidya Prasarak Sanstha's Institute of Pharmaceutical Education, Boradi 425428, India.
2Research Scholar, Sankalchand Patel University, Visnagar 384315, Gujarat, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 6,
Year - 2026
ABSTRACT:
Background: Stability underpins the quality, safety, and efficacy of a pharmaceutical product throughout its shelf life. Chemical, physical, microbiological, and therapeutic degradation pathways can each reduce potency, generate toxic degradants, and alter clinical outcomes. As formulations become more complex, encompassing nanomedicines, biologics, and novel delivery platforms, stability science has taken on renewed importance, and regulators (ICH, FDA, WHO, EMA) now require robust stability data before granting market authorisation. Objective: This review consolidates current understanding of the mechanisms of pharmaceutical instability, the factors that govern them, established and emerging analytical approaches, formulation and packaging countermeasures, the regulatory landscape, and the stability considerations specific to biologics and nanomedicines. Methodology: Peer-reviewed literature published between 2000 and 2024 was surveyed across PubMed, Scopus, Science Direct, and Google Scholar using search terms that included “pharmaceutical stability,” “drug degradation,” “accelerated stability testing,” “ICH guidelines,” “stability-indicating methods,” “forced degradation,” “biologics stability,” and “nanomedicine stability,” supplemented by ICH and WHO guidance and pharmacopoeial standards (USP, BP, IP). Key Findings: Stability reflects the interplay between intrinsic molecular properties and extrinsic environmental stress. ICH-based protocols remain the benchmark for shelf-life assignment, while HPLC, UPLC, DSC, FTIR, and DLS underpin the development of stability-indicating methods. Amorphous solid dispersions, nanocarriers, lyophilisation, and advanced packaging have widened the stabilisation toolkit. Biologics, mRNA therapeutics, and lipid-nanoparticle systems raise stability challenges that traditional frameworks address only in part, and artificial intelligence is emerging as a tool for shelf-life prediction. Conclusion: Stability assessment remains indispensable across the product lifecycle. The continued integration of advanced analytics, formulation science, regulatory compliance, and digital tools should further improve the efficiency and predictive power of stability programmes, particularly for novel modalities.
Cite this article:
Dinesh S. Shinde, Amol R. Pawar, Pankaj S. Patil, Vikas V. Patil. Pharmaceutical Stability Studies: A Comprehensive Review of Mechanisms, Testing Strategies and Emerging Trends. Asian Journal of Research in Chemistry.2026; 19(6):571-8. doi: 10.52711/0974-4150.2026.00081
Cite(Electronic):
Dinesh S. Shinde, Amol R. Pawar, Pankaj S. Patil, Vikas V. Patil. Pharmaceutical Stability Studies: A Comprehensive Review of Mechanisms, Testing Strategies and Emerging Trends. Asian Journal of Research in Chemistry.2026; 19(6):571-8. doi: 10.52711/0974-4150.2026.00081 Available on: https://www.ajrconline.org/AbstractView.aspx?PID=2026-19-6-8